Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

What is wrong with orphan drug policies? Suggestions for ways forward.

Kanavos P, Nicod E.

Value Health. 2012 Dec;15(8):1182-4. doi: 10.1016/j.jval.2012.08.2202. Epub 2012 Oct 25.

2.

What is wrong with orphan drug policies?

Côté A, Keating B.

Value Health. 2012 Dec;15(8):1185-91. doi: 10.1016/j.jval.2012.09.004.

3.

Access to orphan drugs in Europe: current and future issues.

Michel M, Toumi M.

Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):23-9. doi: 10.1586/erp.11.95.

PMID:
22280193
4.

A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.

Liu BC, He L, He G, He Y.

J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30.

PMID:
21119648
5.

Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?

Hughes-Wilson W, Palma A, Schuurman A, Simoens S.

Orphanet J Rare Dis. 2012 Sep 26;7:74. doi: 10.1186/1750-1172-7-74.

6.

[Orphan drugs: some legal, ethical and economics aspects].

Pabst JY.

Rev Epidemiol Sante Publique. 2001 Sep;49(4):387-96. French.

PMID:
11567205
7.

Drugs for rare diseases: mixed assessment in Europe.

[No authors listed]

Prescrire Int. 2007 Feb;16(87):36-42.

PMID:
17323539
8.

Pricing and reimbursement of orphan drugs: the need for more transparency.

Simoens S.

Orphanet J Rare Dis. 2011 Jun 17;6:42. doi: 10.1186/1750-1172-6-42.

9.

The economics of orphan drug policy in the US. Can the legislation be improved?

Peabody JW, Ruby A, Cannon P.

Pharmacoeconomics. 1995 Nov;8(5):374-84. Review.

PMID:
10160072
10.

[Orphan drugs].

Kolár J, Chalabala M, Srámková H.

Ceska Slov Farm. 2001 Mar;50(2):59-65. Czech.

PMID:
11288591
11.

Economic considerations in the provision of treatments for rare diseases.

McCabe C, Edlin R, Round J.

Adv Exp Med Biol. 2010;686:211-22. doi: 10.1007/978-90-481-9485-8_13. Review.

PMID:
20824448
12.

Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.

Schey C, Milanova T, Hutchings A.

Orphanet J Rare Dis. 2011 Sep 27;6:62. doi: 10.1186/1750-1172-6-62.

13.

[Authorization and reimbursement of orphan drugs in an international comparison].

Roll K, Stargardt T, Schreyögg J.

Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16. Review. German.

PMID:
20848380
14.

Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.

Iskrov G, Miteva-Katrandzhieva T, Stefanov R.

Health Policy. 2012 Nov;108(1):10-8. doi: 10.1016/j.healthpol.2012.08.013. Epub 2012 Aug 29.

PMID:
22939047
15.

Access to orphan drugs despite poor quality of clinical evidence.

Dupont AG, Van Wilder PB.

Br J Clin Pharmacol. 2011 Apr;71(4):488-96. doi: 10.1111/j.1365-2125.2010.03877.x.

16.

Evaluating and improving orphan drug regulations in Europe: a Delphi policy study.

Picavet E, Cassiman D, Simoens S.

Health Policy. 2012 Nov;108(1):1-9. doi: 10.1016/j.healthpol.2012.08.023. Epub 2012 Sep 16.

PMID:
22989856
17.

Issues surrounding orphan disease and orphan drug policies in Europe.

Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S.

Appl Health Econ Health Policy. 2010;8(5):343-50. doi: 10.2165/11536990-000000000-00000.

PMID:
20804226
18.

Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.

Arno PS, Bonuck K, Davis M.

Milbank Q. 1995;73(2):231-52. Review.

PMID:
7776947
19.

Pharmaceuticals. Adopt an orphan.

Karr A.

Health Serv J. 1999 Nov 18;109(5681):28. No abstract available.

PMID:
10724720
20.

[Orphan Drugs: Underrated Opportunities for The Developers in Europe].

Tillet Y, Maillols-Perroy AC.

Therapie. 2015 Jul-Aug;70(4):351-7. doi: 10.2515/therapie/2015021. Epub 2015 May 21. French.

PMID:
25997721

Supplemental Content

Support Center